Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Hospital, Westminster Bridge Road, London , United Kingdom.
School of Medicine, University of Nottingham, City Hospital Hucknall Rd , Nottingham , United Kingdom.
Physiol Genomics. 2018 Feb 1;50(2):117-126. doi: 10.1152/physiolgenomics.00053.2017. Epub 2017 Dec 20.
Disruption in the metabolism of lipids is broadly classified under dyslipidemia and relates to the concentration of lipids in the blood. Dyslipidemia is a predictor of cardio-metabolic disease including obesity. Traditionally, the large interindividual variation has been related to genetic factors and diet. Genome-wide association studies have identified over 150 loci related to abnormal lipid levels, explaining ~40% of the total variation. Part of the unexplained variance has been attributed to environmental factors including diet, but the extent of the dietary contribution remains unquantified. Furthermore, other factors are likely to influence lipid metabolism including the gut microbiome, which plays an important role in the digestion of different dietary components including fats and polysaccharides. Here we describe the contributing role of host genetics and the gut microbiome to dyslipidemia and discuss the potential therapeutic implications of advances in understanding the gut microbiome to the treatment of dyslipidemia.
脂质代谢紊乱被广泛归类为血脂异常,与血液中脂质的浓度有关。血脂异常是肥胖等心脏代谢疾病的预测因子。传统上,个体间的巨大差异与遗传因素和饮食有关。全基因组关联研究已经确定了 150 多个与异常血脂水平相关的基因座,解释了总变异的约 40%。部分未解释的差异归因于环境因素,包括饮食,但饮食的贡献程度仍未量化。此外,其他因素也可能影响脂质代谢,包括肠道微生物组,它在不同膳食成分(包括脂肪和多糖)的消化中起着重要作用。在这里,我们描述了宿主遗传和肠道微生物组对血脂异常的影响,并讨论了深入了解肠道微生物组对血脂异常治疗的潜在治疗意义。